Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
NCT04958811Phase 2Active, not recruiting
- Sponsor
- Georgetown University
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tiragolumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Georgetown University. Primary endpoint: Objective Response Rate. Started Dec 2021; status: active, not recruiting.
02
Drugs
tiragolumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04958811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958811.